Investors

Investors

Accelerating the development of new therapies and improving the diagnosis and treatment of serious diseases, we deliver value for our investors and partners, as well as those whose lives we touch.

We Deliver at a Global Scale

Benefits for all stakeholders

The combination of Median’s ground-breaking technology and world-class expertise perfectly positions us to revolutionize the field of medical imaging, transforming data generation, management, and access all around the world. Benefiting patients, health professionals, our partners and investors.

See our board of directors and management team

Our Latest Corporate Presentation

KOL webinar: The eyonis™ Lung Cancer Screening (LCS) REALITY data – What leading U.S. clinical pulmonology experts are saying

Press Releases and Corporate Updates

Latest Press Release

Disclosure of total number of voting rights and number of shares in the capital as of October 31st, 2024

See all press releases

Latest Corporate Update

KOL webinar: The eyonis™ Lung Cancer Screening (LCS) REALITY data – What leading U.S. clinical pulmonology experts are saying

Download

See all corporate updates

Shareholding Structure as of December 31, 2023

Number of shares: 18,404,608

FURUI Medical Science Company Luxembourg8.2

Celestial Successor Fund LP7.0

Abingworth LLP (nominative and non nominative)5.2

Canon Inc5.2

Founders, Management, Employees6.1

Others68.3

Stock Market Data

Median Technologies is listed on Euronext Growth (ISIN: FR0011049824, ticker: ALMDT)

Share price data

View price chart

Analyst Coverage

Median Technologies is followed by the analysts listed below.

Any opinions, estimates, forecasts and recommendations regarding Median Technologies made by these analysts are their own. These opinions, estimates, forecasts and recommendations may or may not represent those of Median’s management.